1Green JD,Kreplak L,Goldsbury C,et al.Atomic force microscopy reveals defeats within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide[J].J Mol Biol,2004,342 (3):877-887.
2Sparr E,Engel MF,Sakharov DV.Islet amyloid polypepiteinduced mechbrone leakage involves uptake of lipids by forming amyloid fibers[J].FEBS Lett.2004,577(1-2):117-120.
3Zhao HL,Lai FM,Tong PC.Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes[J].Diabetes,2003,52(11):2759-2766.
4Steinberg HO,Baron AD.Vascular function,insulin resistance and fatty acids[J].Diabetologia,2002,45 (5):623-634.
5Wang Y,Xu A,Ye J.Alteration in phosphorylation of P20 is associated with insulin resistance[J].Diabetes,2001,50 (8):1821-1827.
6Haynes JM,Hodgson WC,Cooper ME.Rat amylin mediabetes a pressor response in the anaesthetized rat:implications for the association between hypertension and diabetes mellitus[J].Diabetologia,1997,40(3):256-261.
7Ikeda J,Iwata K,Ochi H.Effect of insulin,proinsulin,and amylin on rennin release form penfused rat kidey[J].Metabolism,2001,50(7):763-766.
8Schmitz O,Brock B,Rungby J.Amylin agonists:a novel approach in the treatment of diabetes[J].Diabetes,2004,53(Suppl 3):S233-S238.
3Haataja L, Gurlo T, Huang C J et al. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis[J]. Endocr Rev,2008;29(3):303-316.
4Hull R L,Westermark G T, Westermark Pet al. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes[J]. Clin Endocrinol Metab, 2004;89(8) :3629-3643.
5Hoogenboom H R, De Bruine A P, Hufton S E et al. Antibody phage display technology and its applications [ J ]. Immunotechnology, 1998 ; 4 ( 1 ) : 1-20.
6Popkov M, Rader C, Barbas C F. Isolation of human prostate cancer cell reactive antibodies using phage display technology[J], lmmunol Methods, 2004;291(1-2) : 137-151.
7Goetze JP .Alehagen U, FJyvbjerg A, et al. Chromogranin A as a biomarker in cardiovascular disease [J]. Biomark Med ,2014 ,8 (1) : 133- 140.
8Helle,KB. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system [J]. Results Probl Cell Differ ,2010,50 (1) :2144.
9Han S .Donelan W, Wang H .et al. Novel autoantigens in type 1 diabetes[J].Am J Transl Res ,2013 ,5(4) :379-392.
10Loh YP, Cheng Y, Mahata SK, et al. Chromogranin A and derived peptides in health and disease [J]. Mol Neurosci ,2012 ,48 (2) :347- 356.
